U.S. Capital Wealth Advisors, LLC Aldeyra Therapeutics, Inc. Transaction History
U.S. Capital Wealth Advisors, LLC
- $3.48 Billion
- Q4 2025
A detailed history of U.S. Capital Wealth Advisors, LLC transactions in Aldeyra Therapeutics, Inc. stock. As of the latest transaction made, U.S. Capital Wealth Advisors, LLC holds 14,805 shares of ALDX stock, worth $75,061. This represents 0.0% of its overall portfolio holdings.
Number of Shares
14,805Holding current value
$75,061% of portfolio
0.0%Shares
2 transactions
Others Institutions Holding ALDX
# of Institutions
147Shares Held
39.9MCall Options Held
344KPut Options Held
71.7K-
Knoll Capital Management, LLC Miami, FL5.48MShares$27.8 Million15.99% of portfolio
-
Perceptive Advisors LLC New York, NY5.22MShares$26.5 Million0.06% of portfolio
-
Black Rock Inc. New York, NY3.62MShares$18.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.59MShares$18.2 Million0.0% of portfolio
-
Ardsley Advisory Partners LP Stamford, CT1.9MShares$9.63 Million1.4% of portfolio
About Aldeyra Therapeutics, Inc.
- Ticker ALDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,323,100
- Market Cap $296M
- Description
- Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...